BIOTIME

BTX AMEX
1.180
-0.020
-1.67%
After Hours: 1.180 0 0.00% 17:41 07/16 EDT
Open
1.200
Prev Close
1.200
High
1.200
Low
1.130
Volume
268.29K
Avg Vol (3M)
506.99K
52 Week High
2.610
52 Week Low
0.6600
% Turnover
0.18%
Market Cap
176.58M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers BIOTIME BTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.
MORE >

Recently

Name
Price
%Change